Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Published in: Drugs & Therapy Perspectives 1/2006

01-01-2006 | Disease Management

Patients with asthma should use intermediate-acting inhaled β2-agonists only on an as-needed basis

Published in: Drugs & Therapy Perspectives | Issue 1/2006

Login to get access

Excerpt

Intermediate-acting (fast-acting) inhaled β2-adrenoceptor agonists (β2-agonists) are now recommended to be used exclusively as needed. Regularly scheduled (or frequent as-needed) use of intermediate-acting inhaled β2-agonists may result in tolerance to the bronchodilator, increased airway responsiveness to allergen, worsened asthma control and, most importantly, undertreatment resulting from over-reliance on a symptom reliever. …
Literature
1.
Cockcroft DW. As-needed inhaled β2-adrenoceptor agonists in moderate-to-severe asthma. Treat Respir Med 2005; 4(3): 169–74PubMedCrossRef
2.
National Institutes of Health. Global Initiative for Asthma: pocket guide for asthma management and prevention. Publication No. 95-3659B. Bethesda (MD): National Institute of Health, National Heart Lung and Blood Institute, 1998
3.
Boulet LP, Becker A, Berube D, et al. Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. CMAJ 1999; 161: Sl–61
4.
Walters EH, Walters J. Inhaled short-acting beta 2-agonist use in asthma: regular versus as needed treatment. Cochrane Database Syst Rev 2003; (2): CD001285PubMed
5.
Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994; 149: 604–10PubMed
6.
Abramson MJ, Bailey MJ, Couper FJ, et al. Are asthma medications and management related to deaths from asthma? Am J Respir Crit Care Med 2001; 163: 12–8PubMed
7.
Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391–6PubMedCrossRef
8.
Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax 1993; 48: 134–8PubMedCrossRef
9.
Cockcroft DW, McParland CP, Britto SA, et al. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; 342: 833–7PubMedCrossRef
10.
Cockcroft DW, O’Byrne PM, Swystun VA, et al. Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J Allergy Clin Immunol 1995; 96: 44–9PubMedCrossRef
11.
Cockcroft DW, Swystun VA, Bhagat R. Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am J Respir Crit Care Med 1995; 152: 1485–9PubMed
12.
Bhagat R, Swystun VA, Cockcroft DW. Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. J Allergy Clin Immunol 1996; 97: 47–52PubMedCrossRef
13.
Gauvreau GM, Jordana M, Watson RM, et al. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med 1997; 156: 1738–45PubMed
14.
Swystun VA, Gordon JR, Davis EB, et al. Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol. J Allergy Clin Immunol 2000; 106: 57–64PubMedCrossRef
Metadata
Title
Patients with asthma should use intermediate-acting inhaled β2-agonists only on an as-needed basis
Publication date
01-01-2006
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives / Issue 1/2006
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.2165/00042310-200622010-00004

Other articles of this Issue 1/2006

Drugs & Therapy Perspectives 1/2006 Go to the issue

Product Introductions

New in the marketplace

Drug and Profile Reports

Imiquimod in superficial basal cell carcinoma: profile report

Disease Management

Treatment of gouty arthritis requires both immediate action and long-term strategies to put out the ‘fire’

Drug and Profile Reports

Eplerenone reduces deaths from heart failure after a heart attack and effectively treats hypertension

Drug Reactions and Interactions

First reports of adverse drug reactions in recent weeks

Disease Management

Ensure adequate and individualised symptomatic pain treatment of HIV-associated distal symmetrical polyneuropathy